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Introduction: ATLAS compared bevacizumab plus erlotinib (B+E) 
with bevacizumab plus placebo (B+P) as maintenance therapy after 
first-line bevacizumab plus chemotherapy (B+C) for advanced non-
small-cell lung cancer (NSCLC). Prespecified biomarkers were pro-
spectively evaluated.
Methods: Tumor samples were analyzed for: epidermal growth fac-
tor receptor (EGFR) expression (immunohistochemistry [IHC]); 
EGFR gene copy number (fluorescence in-situ hybridization [FISH]); 
EGFR mutations (exon 19 deletions/L858R mutations); and KRAS 
mutations (exons 2/3). Progression-free survival (PFS) and overall 
survival (OS) were estimated.
Results: Of 743 patients randomized to receive maintenance treat-
ment (after four cycles of B+C without progression), 190 (B+E) and 
177 (B+P) were evaluable for biomarker status. Median PFS (from 
randomization) was 4.4 months (B+E) versus 3.7 months (B+P; 
hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.57–0.99), 
which was numerically similar to the intent-to-treat PFS. PFS ben-
efit of B+E was observed across most biomarker subgroups. EGFR 
IHC, EGFR FISH, and EGFR/KRAS mutation status were not predic-
tive of outcome. B+E-treated patients with EGFR mutation-positive 
NSCLC had longer PFS compared with B+P-treated patients (HR, 
0.44; 95% CI, 0.22–0.86; p = 0.0139). Patients with KRAS wild-type 
disease had significant PFS improvements with B+E, compared with 
B+P (HR, 0.66; 95% CI, 0.485–0.914; p = 0.0105). No OS benefit of 
B+E was observed.
Conclusions: Patients with KRAS wild-type or EGFR mutation-pos-
itive NSCLC derived PFS benefits from B+E. However, EGFR IHC, 
EGFR FISH, and EGFR or KRAS mutation status were not strongly 
predictive of survival. A larger sample size would be needed to con-
firm the initial trends observed in this study.
Key Words: Erlotinib; Bevacizumab; Non-small-cell lung cancer; 
Biomarkers; Maintenance.
(J Thorac Oncol. 2014;9: 1411–1417)
The characterization of the pathogenesis of non-small-cell lung cancer (NSCLC) has led to the development of molec-
ularly targeted agents such as epidermal growth factor receptor 
(EGFR) tyrosine-kinase inhibitors (TKIs) and anti-vascular 
endothelial growth factor monoclonal antibodies. Addition 
of the vascular endothelial growth factor -specific antibody 
bevacizumab to chemotherapy prolongs progression-free 
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survival (PFS) (Eastern Cooperative Oncology Group 4599 
study1/AVAiL study2) and overall survival (OS) (E4599) in 
NSCLC. Erlotinib, an EGFR TKI, improves PFS and OS in 
the second- and third-line treatment of NSCLC,3 in the main-
tenance setting4 and prolongs PFS in the first-line treatment 
of EGFR mutation-positive NSCLC.5,6 A combination of 
bevacizumab and erlotinib, each targeting different molecu-
lar pathways, represents a rational therapeutic approach for 
advanced NSCLC.
ATLAS (Avastin Tarceva Lung Adenocarcinoma 
Study) was a randomized, double-blind, placebo-controlled, 
phase III trial comparing bevacizumab maintenance therapy 
with or without erlotinib, after completion of chemotherapy 
with bevacizumab for the first-line treatment of advanced 
NSCLC. The primary analysis showed that adding erlo-
tinib to bevacizumab in the maintenance phase significantly 
improved PFS by 1 month, but did not prolong OS.7 Although 
generally well tolerated, the two-drug regimen was associ-
ated with more adverse events than either regimen alone and 
was not recommended as a new post-chemotherapy standard 
of care.
Some patient subgroups derive particular clinical ben-
efit from erlotinib. At the time of ATLAS initiation, mark-
ers of interest for erlotinib included EGFR mutations, KRAS 
mutations, EGFR gene copy number (by fluorescence in-
situ hybridization [FISH]) and EGFR protein expression 
(by immunohistochemistry [IHC]).8,9 Biomarker analyses 
were prospectively defined to establish whether specific sub-
groups derive more pronounced benefit from this two-drug 
combination.
METHODS
Trial Design and Patients
The ATLAS trial (ClinicalTrials.gov identifier 
NCT00257608) was reported in detail previously.7 A 
CONSORT diagram (intent-to-treat [ITT] population and bio-
marker-evaluable population [BEP]) is shown (Fig. 1; see also 
Supplemental Appendix, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A633). Further details are reported 
in the Supplemental Appendix (Supplemental Digital Content 
1, http://links.lww.com/JTO/A633).
The primary objective was to compare the PFS of 
patients with advanced NSCLC who received bevacizumab 
plus erlotinib versus bevacizumab plus placebo after comple-
tion of four cycles of chemotherapy plus bevacizumab with-
out evidence of disease progression or significant toxicity. 
Secondary objectives were to compare safety and OS between 
arms. Prospective biomarker analyses were carried out on 
tissue samples from consenting patients. Patient eligibility, 
randomization and masking are described (Supplemental 
Appendix, Supplemental Digital Content 1, http://links.lww.
com/JTO/A633).
The study was conducted in accordance with Good 
Clinical Practice guidelines and approved by the review board/
local ethics committees at each participating center. Patients 
provided written informed consent for participation in the 
study, with separate consent for biomarker analysis. There 
were no inducements for tissue collection.
Biomarker Collection and Analysis
Archival tumor samples were collected (paraffin tissue 
blocks or unstained slides). Manual or laser capture micro-
dissection was used. Analyses were carried out at Genentech 
Inc., South San Francisco, CA. Tests were prioritized as fol-
lows: EGFR mutation status (exon 19 deletions and L858R 
mutations only), KRAS mutation status (exons 2 or 3), EGFR 
IHC, and EGFR FISH. Full details of the testing methodology 
are provided online (Supplemental Appendix, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A633).
Statistical Analysis
PFS and OS were summarized by treatment arm within 
each of the biomarker subgroups. The hazard ratio (HR) 
was estimated using an unstratified Cox regression model. 
Kaplan–Meier methodology was used to estimate median 
PFS/OS and construct Kaplan–Meier curves. The difference 
in PFS or OS between the treatment arms was compared using 
unstratified log-rank tests.
RESULTS
Baseline characteristics of the ITT population and BEP 
were well balanced, and generally similar, with the excep-
tion that there were slightly fewer never smokers and prior 
surgeries in the BEP (Table 1). The PFS in the BEP and ITT 
FIGURE 1.  CONSORT diagram for biomarker-evaluable 
patients. Note: a full study CONSORT diagram is available 
in Johnson et al.7 Note: Patients with missing or unevaluable 
biomarker status were excluded from the biomarker evalu-
able patients. EGFR, epidermal growth factor receptor; FISH, 
fluorescence in-situ hybridization; IHC, immunohistochemis-
try; ITT, intent-to-treat.
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population is shown (Fig. 2A and B). Biomarker status was 
balanced across the treatment arms, with the exception that 
there were more patients with EGFR FISH-negative status in 
the bevacizumab plus placebo group, compared with the beva-
cizumab plus erlotinib group (Table 2).
Some patients had more than one mutation/biomarker 
assessed as positive, with overlap in patients testing posi-
tive for EGFR FISH, EGFR mutations, and KRAS mutations 
(Supplemental Figure 1, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A634).
Benefit, as measured by PFS, was observed across 
most biomarker subgroups (Fig. 3; Supplemental Figure 2, 
Supplemental Digital Content 3, http://links.lww.com/JTO/
A635), including patients with EGFR wild-type disease. EGFR 
IHC, EGFR FISH, EGFR mutation status, and KRAS mutation 
status were not strongly predictive of outcome by treatment arm 
TABLE 1.  Patient Demographics of the ITT Population and BEP (July 18, 2008)
Characteristic
ITT Population BEP
Bevacizumab Plus Placebo 
(n = 373)
Bevacizumab Plus Erlotinib 
(n = 370)
Bevacizumab Plus Placebo 
(n = 177)
Bevacizumab Plus Erlotinib 
(n = 190)
Age (yr)
  Mean (SD) 62.8 (10.8) 62.9 (10.3) 63·2 (10.3) 63.4 (10.4)
  18–40 (%) 9 (2.4) 7 (1.9) 3 (1.7) 3 (1.6)
  41–64 (%) 180 (48.3) 194 (52.4) 89 (50.3) 96 (50.5)
  ≥ 65 (%) 184 (49.3) 169 (45.7) 85 (48.0) 91 (47.9)
Sex, n (%)
  Male 196 (52.5) 193 (52.1) 90 (50.8) 101 (53.2)
  Female 177 (47.4) 177 (47.8) 87 (49.2) 89 (46.8)
ECOG PS at randomization, n (%)
  0 125 (33.8) 127 (34.6) 54 (30.7) 58 (30.7)
  ≥ 1 245 (66.2) 240 (65.4) 122 (69.3) 131 (69.3)
Clinical stage, n (%)
  IIIB 37 (9.9) 32 (8.6) 18 (10.2) 16 (8.4)
  IV 310 (83.1) 317 (85.6) 141 (80.1) 159 (83.7)
  Recurrent 25 (6.7) 21 (5.6) 17 (9.7) 15 (7.9)
Histology, n (%)
  Adenocarcinoma 309 (82.8) 301 (81.4) 143 (80.8) 157 (82.6)
  Large-cell carcinoma 26 (6.9) 30 (8.1) 14 (7.9) 12 (6.3)
  Squamous-cell carcinoma 6 (1.6) 11 (2.9) 5 (2.8) 9 (4.7)
  Other 32 (8.6) 28 (7.6) 15 (8.5) 12 (6.3)
Smoking status, n (%)
  Never 66 (17.7) 61 (16.5) 21 (11.9) 19 (10.0)
  Former 178 (47.7) 180 (48.6) 85 (48.3) 102 (53.7)
  Current 129 (34.5) 129 (34.8) 70 (39.8) 69 (36.3)
Chemotherapy, n (%)
  Carboplatin/paclitaxel 174 (46.6) 178 (48.1) 85 (48.0) 94 (49.5)
  Carboplatin/gemcitabine 104 (27.8) 105 (28.4) 53 (29.9) 59 (31.1)
  Carboplatin/docetaxel 54 (14.5) 46 (12.4) 29 (16.4) 22 (11.6)
  Cisplatin/gemcitabine 32 (8.6) 33 (8.9) 6 (3.4) 11 (5.8)
  Other 9 (2.4) 8 (2.2) 4 (2.3) 4 (2.1)
Prior radiotherapy, n (%)
  Yes 316 (84.7) 305 (82.4) 143 (80.8) 158 (83.2)
  No 57 (15.3) 65 (17.6) 34 (19.2) 32 (16.8)
Prior surgery, n (%)
  Yes 42 (11.3) 45 (12.2) 10 (5.6) 12 (6.3)
  No 331 (88.7) 325 (87.8) 167 (94.4) 178 (93.7)
Prior systemic adjuvant or neo-adjuvant therapy, n (%)
  Yes 345 (92.5) 348 (94.1) 161 (91.0) 179 (94.2)
  No 28 (7.5) 22 (5.9) 16 (9.0) 11 (5.8)
B + E, bevacizumab plus erlotinib; B + P, bevacizumab plus placebo; BEP, biomarker-evaluable population; ITT, intent-to-treat; ECOG PS, Eastern Cooperative Oncology Group 
performance status; ITT, intent-to-treat.
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TABLE 2.  Biomarker Status at Baseline (July 18, 2008 Data Cutoff)
Bevacizumab Plus Placebo (n = 373) Bevacizumab Plus Erlotinib (n = 370) All Randomized Patients (n = 743)
EGFR IHC
  Total, n (%) 121 137 258
   Positive 89 (73.6) 102 (74.5) 191 (74.0)
   Negative 32 (26.4) 35 (25.5) 67 (26.0)
EGFR FISH
  Total, n (%) 102 94 196
   Positive 41 (40.2) 46 (48.9) 87 (44.4)
   Negative 61 (59.8) 48 (51.1) 109 (55.6)
EGFR mutation status
  Total, n (%) 170 177 347
   Mutated 25 (14.7) 27 (15.3) 52 (15.0)
   Wild type 145 (85.3) 150 (84.7) 295 (85.0)
KRAS mutation status
  Total, n (%) 161 171 332
   Mutated 46 (28.6) 47 (27.5) 93 (28.0)
   Wild type 115 (71.4) 124 (72.5) 239 (72.0)
Percentages are based on patients without missing information.
EGFR, epidermal growth factor receptor; FISH, fluorescence in-situ hybridization; IHC, immunohistochemistry.
FIGURE 2.  PFS in patients included in the ATLAS (A) biomarker-evaluable and (B) ITT populations. OS in the ATLAS (C) 
biomarker-evaluable and (D) ITT populations (data cutoff: July 18, 2008). B + E, bevacizumab plus erlotinib; B + P, bevacizumab 
plus placebo; HR, hazards ratio; ITT, intent-to-treat; OS, overall survival; PFS, progression-free survival.
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(Supplemental Figure 2A–D, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A635), although there were trends 
observed for EGFR FISH and EGFR mutation status. In the 
BEP, patients with EGFR mutation-positive or KRAS wild-type 
NSCLC derived the greatest PFS benefit from the combination 
of bevacizumab and erlotinib, compared with bevacizumab 
and placebo (Fig. 3A and B). Figure 4 shows the relationship 
between EGFR IHC, EGFR FISH, EGFR mutations, KRAS 
mutations, and efficacy outcomes. The OS for the BEP and the 
ITT population is shown in Figure 2C and D.
Median OS from the time of randomization for patients 
with EGFR mutation-positive NSCLC was 14.5 months in 
the bevacizumab plus erlotinib arm, and 14.3 months in the 
bevacizumab plus placebo arm. A trending OS benefit was 
observed with the addition of erlotinib in this patient subset: at 
the first data cutoff, the HR was 0.76 (95% confidence interval 
[CI], 0.30–1.94) and at the second data cutoff, the HR was 0.46 
(95% CI, 0.21–1.02). Median OS for patients with KRAS wild-
type NSCLC was 15.1 months in the bevacizumab plus erlo-
tinib group and 13.1 months for the bevacizumab plus placebo 
group. Again, a trend towards an OS benefit was seen with the 
addition of erlotinib, although again the CI crossed 1.0 (Fig. 4). 
Finally, median OS for patients with KRAS mutation-positive 
NSCLC was 13.4 months in the bevacizumab plus erlotinib 
group and 10.7 months in the bevacizumab plus placebo group.
DISCUSSION
Patients with EGFR mutation-positive NSCLC and 
KRAS wild-type NSCLC showed significant PFS improve-
ments with maintenance bevacizumab plus erlotinib, com-
pared with bevacizumab plus placebo. These results support 
the PFS benefit observed in erlotinib-treated EGFR mutation-
positive NSCLC in large, randomized, controlled clinical tri-
als,5,6 including the phase III SATURN trial of maintenance 
erlotinib.8 SATURN also reported PFS benefits with erlo-
tinib in the EGFR FISH-positive subset, and found that 
KRAS mutations were prognostic for reduced PFS.4,8,10 This 
latter result differed from the observation in this analysis of 
the ATLAS data. Analyses of the BR.21 study suggested that 
greater survival benefits were seen in patients with EGFR 
FISH-positive NSCLC, EGFR mutation-positive NSCLC, 
and KRAS wild-type NSCLC.9 A recent meta-analysis of 23 
trials (13 front-line, seven second-line, and three maintenance; 
n = 14,570) reported that EGFR TKI treatment prolonged PFS 
in all settings in EGFR mutation-positive NSCLC.11 In that 
meta-analysis, EGFR TKI therapy did not have a significant 
impact on OS in patients with either EGFR mutation-positive 
or mutation-negative disease. Despite a benefit of EGFR TKI 
treatment in multiple lines, BioLOGUE (Biomarkers Lung 
Oncology Group Understanding Erlotinib; Supplemental 
Appendix, Supplemental Digital Content 1, http://links.lww.
com/JTO/A633) recommended that EGFR IHC, EGFR FISH, 
and KRAS mutations should not be used to select patients for 
erlotinib after first-line chemotherapy.12 Although EGFR muta-
tion testing was acknowledged to be of value in first-line therapy 
selection, BioLOGUE recommended that it should not be used 
to select for maintenance or second-line erlotinib treatment 
(EGFR mutation status was shown to be predictive for erlo-
tinib-treated PFS, but only prognostic for OS, in their pooled 
analysis of phase III data). The lack of a predictive marker for 
OS in erlotinib-treated patients in the BioLOGUE report and 
the Lee meta-analysis is consistent with the findings from this 
study. The limitations of OS as an end point should also be 
considered, particularly the confounding influence of post-
study crossover, with 41% of patients being treated with sec-
ond-line erlotinib therapy.7 A larger sample size will be needed 
to confirm the trends observed in this study. Comprehensive 
guidelines on mutation testing for NSCLC were recently pub-
lished, confirming the value of EGFR mutation testing in first-
line therapy (Supplemental Appendix, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A633).
The BioLOGUE meta-analysis also found that KRAS 
mutations were a negative prognostic marker for survival when 
patients were treated with erlotinib or placebo after chemo-
therapy, but were not predictive of erlotinib efficacy, which 
is consistent with this analysis. Single-arm and retrospec-
tive studies have suggested a poor prognosis for patients with 
KRAS mutation-positive NSCLC (Supplemental Appendix), 
however owing to the nature of these studies, the predictive 
role of KRAS mutations with regard to erlotinib efficacy cannot 
be definitively ascertained.13–15 Because all patients in ATLAS 
received bevacizumab, there are inherent differences in patient 
populations; any comparison with studies of erlotinib mono-
therapy should, therefore, be undertaken with caution.
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FIGURE 3.  Progression-free survival (PFS) in patients with (A) EGFR mutation-positive tumors (B) KRAS wild-type tumors. B + E, 
bevacizumab plus erlotinib; B + P, bevacizumab plus placebo; HR, hazards ratio;
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In summary, these biomarker analyses suggest that patients 
in most biomarker subgroups derived PFS benefits, and patients 
with EGFR mutation-positive or KRAS wild-type NSCLC may 
derive the greatest PFS benefit from bevacizumab plus erlotinib. 
EGFR IHC and KRAS mutation status were not strongly pre-
dictive of clinical outcome. EGFR FISH status trended towards 
being predictive of PFS, but not OS. EGFR mutation status was 
the only marker likely to be a consistent predictor for PFS and 
OS in larger trials. However, it should be acknowledged that 
tumor molecular profiles are known to change throughout treat-
ment and the reported results reflect tumor status at baseline. It 
should also be acknowledged that reported sample sizes were 
small. A larger sample size would be needed to confirm the sig-
nificance of the trends observed in this study.
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FIGURE 4.  Progression-free survival 
(PFS) and overall survival (OS) in 
biomarker subgroups. B + E, bevaci-
zumab plus erlotinib; B + P, beva-
cizumab plus placebo; HR, hazards 
ratio.
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